



medibio

INVESTOR DECK

ASX: MEB
OTCPINK: MDBIF

FEBRUARY 2021

FORWARD LOOKING STATEMENTS

The purpose of the presentation is to provide an update of the business of Medibio Limited (**ASX:MEB**) (**OTCPINK: MDBIF**). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification.

Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Medibio Limited and should not be relied upon as an independent source of information. Please contact Medibio Limited and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified.

None of Medibio Limited, or any of its affiliates or associated companies (or any of their officers, employees, contractors or agents (the Relevant Persons)) makes any representation or warranty as to the accuracy, completeness or reliability of the information, or the likelihood of fulfilment of any forward looking statement or any outcomes expressed or implied in any forward looking statements.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks,

uncertainties and other factors, many of which are outside Medibio Limited's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks.

Because actual results could differ materially to assumptions made and Medibio Limited's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. Except as required by applicable law or the ASX listing rules, the Relevant Persons disclaim any obligation or undertaking to publicly update any statements in this presentation, whether as a result of new information or future events.

This presentation should not be relied on as a recommendation or forecast by Medibio Limited. Nothing in this presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.



LOOKING AT MENTAL HEALTH OBJECTIVELY

A mental health technology company pioneering the use of Artificial Intelligence, deep learning algorithms and neural network methodology to identify biological markers and patterns to aid in early detection and screening of mental health conditions.

ASX: MEB
OTCPINK: MDBIF

Amounts shown in AUD

Market Cap as at 28/1/2021 **\$13.5M**

Share price as at 9 Dec 2020 0.9cent

Issued Shares 1,347B

Listed 12/2021 Options convertible at 3 cents 836M

Net Assets at June 2020 **\$12.6M**

TOP 5 SHAREHOLDERS

9.8% **FIDELITY (HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED)**

4.1% **ROOKHARP CAPITAL PTY LTD**

3.9% **CLAUDE SOLITARIO**
Co-founder and Managing Director

2.2% **CITICORP NOMINEES PTY LTD**

2.0% **UBS NOMINEES PTY LTD**

TOP 20



36%

ESOP program for the
benefit of depression and
other mental health disorders

THE PROBLEM



Current diagnostic tests rely on
**clinical interviews with
subjective interpretation**

OUR SOLUTION



Identification of biomarkers and
patterns based on the patient's own
biological data to **objectively aid in
the early detection and screening
of mental health conditions**

WHY INVEST IN MEDIBIO?



EARLY REVENUE POTENTIAL

Medibio's corporate mental well-being app gaining market traction: early revenue imminent.



SUPERIOR VALUE PROPOSITION

Objective, data-driven biological markers and patterns identified **during sleep period** rather than subjective assessment.



INNOVATIVE TECHNOLOGY

The potential to be the world's first objective diagnostic aid of a largely intangible health epidemic: depression



REGULATORY APPROVALS UNDERWAY

Breakthrough Technology Designation
FDA 510K
CE Mark
De Novo



TARGETING A LARGE MARKET

Depression is estimated to cost US economy US\$210 billion a year with the cost in Australia estimated at \$12.6 billion annually



PATENT PROTECTED TECHNOLOGY

Significant revenue opportunities in each market



Business Units

REGULATED

NON-REGULATED



Sleep Staging



Depressive Burden



Consumer App
(in development)



Corporate Health (in-market)

DEPRESSIVE BURDEN TRIAL (SADB) TO VALIDATE MEB-001

MEB-001 is a software medical device that consists of 3 main components:

- 1 **The sleep staging algorithms; overlaid by**
- 2 **Resting heart rate and heart rate variability algorithms, that will lead to:**
- 3 **The Depressive Burden Analysis**

Our team in Minneapolis is currently undertaking a clinical trial known as the

“Sleep Analysis of Depressive Burden”

The purpose of the trial is to clinically validate MEB-001 as a medical device

MEB-001 aims to provide the clinician with an objective, data-driven approach, to assist in the diagnosis of depression, based on the patient’s own biological data.



Granted CE Mark in January 2021 enabling sale of MEBSleep in the European Economic Community

The company is currently in detailed discussions with the FDA regarding its 510(k) application that will enable commercialisation in the USA.



MEBSleep is able to identify the sleep stages in 2 minutes what would normally take a clinician, anywhere between 1 and 2 hours



It is this characteristic that inspired our regulatory team to apply for a 510(k) and CE Mark clearance for MEBSleep, opening up the possibility of generating early revenue



In January 2021 Medibio was granted CE Mark, which enables the company to commercialise in the European Economic Community.

CLINICAL TRIAL AGREEMENT WITH MEDBRIDGE HEALTHCARE LLC IN THE USA

The closure of sleep clinics in Minneapolis due to COVID-19 lockdown, has slowed our depressive burden trial.

In order to increase recruitment, Medibio signed a Clinical Trial Agreement with MedBridge Healthcare LLC in the USA.

MedBridge is the leading provider of sleep laboratory management services in the United States, operating over 130 sleep disorder diagnostic centres.

MedBridge is a valued partner for trial patient recruitment, and importantly, will be a source of market intelligence as we progress through the trial.





Depressive Burden Platform MEB-001

SaaS model based on
a price-per-report



Corporate Health

Enterprise license based
on a corporation's
total workforce



Consumer App

Free download +
pay per functionality/
subscription model



An **early intervention** software program providing objective data to manage and improve **workforce mental health**.

ilumen provides actionable and valuable insights.



We **close the loop** for employers so they may measure and manage their people's mental well-being

BENEFITS OF ILUMEN™



FOR EMPLOYEES


For employees, ilumen™ provides:

- **The ability to track biometrics over time with a wearable device**
- **Access to mental well-being assessments via mobile or website**
- **Tools to learn about strategies to better cope with managing life at work, personal development plans, stress, and strain**
- **Ability to measure, monitor, and improve overall well-being**

Ilumen provides data-driven feedback to help employees take an active role in their own mental well-being by providing them with the tools to understand the difference between a bad mood and a potentially serious health threat.

“Thank you for your concern, following on from this I have booked in some time with the Employee Assistance Program.”

- Ilumen™ user



FOR EMPLOYERS

For employers, ilumen provides:

- **Monitor the impact of mental health programs implemented**
- **Access real-time de-identified aggregate dashboards of employee well-being**
- **Gain a dynamic understanding of their workforce – what the workforce needs and how to help**
- **Optimise workforce performance, minimise risk, and offer better care for employees**
- **Make informed decisions based on workforce data**
- **Provide metrics on workforce capability to clients, suppliers, insurers, etc.**

Ilumen™ helps employers to build the strength of their workforce by bringing science, not stigma, to the conversation around mental well-being and improving the lives of all that work to make organisations a success.

LICENSE FEES

LICENSE FEES


medibio



Compass industry sectors serviced




COMPASS CLIENT COMPANIES, POTENTIAL ILUMEN LICENSEES



Discussions are progressing with Compass HQ and Compass companies regarding implementation across Compass staff and clients

NON-REGULATED PATH (CONSUMER)



Full spectrum mental wellness with three components to help measure, track, and manage:

BIOMETRICS ASSESSMENT

Biometrics are at the core of Medibio's mental health perspective. The consumer product translates this 'language of the body' in three ways: Cardiac (HR), Activity, and Sleep along with an Overall Stress score. The Biometrics timeline allows users to track and identify potential areas of concern, recognize patterns, and identify where stress is showing up.

PSYCHOMETRIC ASSESSMENT

In addition to objective measurement, an individual's level of *perceived stress* is key to understanding the full stress landscape. The Psychometric Assessment is a short series of questions to determine the level of stress users think they are experiencing. The application invites users to participate in this 'self-check' every two weeks.

GOALS & ACTIVITIES

Finally, the goals and activities section is filled with tools for self-reflection and actionable behavior modification to address the data feedback users receive from other areas of the application. *Setting goals, journaling, drawing, or participating in a quick breathing exercise* are some of the resources available to help lower distress, create eustress, and encourage new habits.

33B

new app downloads
globally in Q3

\$28B

spent on apps
(up 20%)

180B

hours each month of July,
August, September 2020
using apps (up 25%)

\$73B

invested in mobile
companies, an increase
of 27% from 2019



The mobile data and analytics firm had earlier suggested that the COVID-19 pandemic would have a long-lasting impact on consumer mobile behavior, as it advanced mobile by at least two to three years ahead of pace. This continued to be true in the third quarter, with all major mobile trends seeing increases. - Tech Crunch

LOOKING FORWARD - 2021 MAJOR MILESTONES

We look forward with a great deal of confidence to achieving a number of significant milestones during 2021 calendar year

Securing ilumen licenses for Compass companies and Compass client companies globally



Securing ilumen licenses in Australia as borders re-open



Commercialising MEBsleep in the EEC following CE Mark approval in January 2021



Commercial launch of our Consumer App in US



Completing the Depressive Burden trial for the De Novo application for MEB-001, for the world's first objective test for depression



BOARD OF DIRECTORS



CLAUDE SOLITARIO
Managing Director
Founder



PETER CARLISLE
Non - Executive Director
Managing Director, Olympics &
Action Sports, Octagon Worldwide



MELANIE LEYDIN
Director & Joint Company
Secretary
CA, FGIA



MATTHEW WATKINS
Joint Company Secretary
B. Bus. (Acc) Swinburne, CA

GROWTH & ADVOCACY ADVISORY BOARD



PETER CARLISLE
Managing Director, Olympics &
Action Sports, Octagon Worldwide



MICHAEL PHELPS
Mental Health Advocate



PATRICK KENNEDY
Former US Congressman
Founder, Kennedy Forum

EXECUTIVE TEAM


medibio



CLAUDE SOLITARIO
Managing Director
Founder



ARCHIE DEFILLO
Chief Medical Officer



MASSIMILIANO GRASSI
Head of Artificial Intelligence



DR GIAMPAOLO PERNA
Clinical Consultant



JENNIFER SOLITARIO
Senior Vice President
Corporate Health



SARAH MELLEN
Creative Director



ERNIE TURSICH
Principal Quality and
Regulatory Affairs



KELLY TRUPKOVIC
Partnerships and Marketing
Manager APAC



RENEE STANTON-HORNE
Operations and
Accounts Manager



medibio

CLAUDE SOLITARIO
Managing Director

Melbourne

Level 4, 100 Albert Road
South Melbourne VIC
3205

United States HQ

8696 Eagle Creek Circle
Savage, MN 55378